Ki (the inhibitor concentration that gives the half-maximum effect) of 3.5 and 0.7 mM after 2 and 18 h incubation, respectively, and is essentially identical between the basal and insulin-stimulated adipocytes. The inhibition develops with a first-order rate constant of approximately 0.12/h at 4VC. These results indicate that furosemide inhibits glucose transport in adipocytes by directly inactivating transport carriers of both plasma membranes and microsomal reserve pool. This inactivation of glucose carrier may play a part in the diureticinduced glucose intolerance frequently observed during diuretic therapy. Introduction Significant glucose intolerance often develops in patients re-
Introduction
Significant glucose intolerance often develops in patients receiving prolonged treatment with diuretic agents, e.g., furose-mide, thiazide, etc. (1) (2) (3) . The exact mechanisms operative in this effect remain unclear and controversial. The postulated mechanisms fall into two broad classes: (a) due to alterations in pancreatic insulin secretion (4) , and (b) due to extrapancreatic effects independent of insulin secretion, such as decreased glucose utilization or transport, and/or decreased insulin sensitivity at the peripheral tissue level (5, 6) .
Alterations in carbohydrate economy conceivably may be due to effects of the diuretic molecule at any of the specific loci that govern such economy. Depletion of total body potassium stores is known to cause glucose intolerance by reducing pancreatic beta cell responsiveness to glucose (7) (8) (9) . More recently, Helderman et al. (10) performed glucose clamp studies on normal volunteers and concluded that thiazideinduced glucose intolerance is a result of potassium depletion, which reduces insulin output by the above mechanism.
However, there is also a body of experimental and clinical evidence that suggests that mechanisms independent of pancreatic insulin output or potassium balance may contribute to glucose intolerance caused by diuretics, especially of the benzothiadiazine class (6, 11) . We have previously shown that furosemide inhibits glucose transport directly in human erythrocytes (12) . We now extend our observations to an insulinsensitive tissue, e.g., adipocytes, to show that furosemide inhibits basal and insulin-stimulated glucose transport by directly interacting with the glucose carrier molecule. We suggest that this direct inactivation of glucose carrier may contribute significantly in the glucose intolerance observed during diuretic therapy.
Hoffman LaRoche, Inc. (Nutley, NJ). Insulin (porcine crystalline) was from Eli Lilly & Co. (Indianapolis, IN). All other chemicals were standard commercial products of reagent grade quality.
Isolation ofadipocytes. Adipocytes were isolated from the epididymal fat pads of Sprague Dawley (150-200 g) male rats given free access to lab chow. Fat cells were prepared by the method described by Rodebell (13) and modified as follows. Minced fat pads were put in several 25-ml polyethylene scintillation vials with 15 ml of Krebs-Ringer bicarbonate buffer containing collagenase (1.5 mg/ml), bovine serum albumin (40 mg/ml), and D-glucose (3 mM) as described (14) . The vials were then gassed briefly (10-20 s) with a 95% 02:5% CO2 mixture, sealed, and incubated with gentle shaking at 370C for I h, at the end of which time the suspension was filtered through a nylon mesh to remove all extraneous tissue. The fat cells were then washed four times in a Krebs-Ringer buffer containing bovine serum albumin (40 mg/ ml) and D-glucose (3 mM) (this buffer is referred to as incubation buffer) by centrifugation (900 g for I min, which gives 80-90% hematocrit).
Preparation of 150,000 g total particulate fraction. Isolated fat cells were hypotonically lysed by vortexing the cells for 60 s in a hypotonic buffer containing MgCI2 (2.5 mM), CaCl2 (0.1 mM), and KHCO3 (1 mM) adjusted to pH 7.2. The suspension was then centrifuged (at 1,000 g for 1 min), the resulting supranatant (containing fat cake and unlysed cells) were separated from lysate and the lysates were pooled and stored on ice. This procedure was repeated with subsequent supranatants four times until only predominantly the fat cake remained, which was discarded. The lysates were spun down in a Beckman ultracentrifuge (Beckman Instruments, Inc., Fullerton, CA) at 150,000 g for 60 min at 5°C. The 150,000-g pellet was then resuspended in the hypotonic buffer referred to above and stored in liquid nitrogen until used.
Preparation ofplasma membrane and microsomefractions. Plasma and microsomal membrane fractions were prepared by the differential centrifugation method described by McKeel and Jarett (I 5) and modified by Cushman and Wardzala (16) . Using a medium (medium 1) composed of 10 mM Tris HCI, pH 7.4, EDTA (I mM), and sucrose (0.25 M). Where insulin and/or furosemide-treated cells were used furosemide and/or insulin was also added to medium 1. The suspension was then transferred in 30-ml aliquots to a glass homogenizer (Arthur H. Thomas Co., Philadelphia, PA) with the pestle rotating at 2,000 rpm. During the homogenization the homogenizer was kept in ice. The homogenate was then centrifuged at 16,000 g for 15 min. The fat cake was discarded. To isolate the microsomal membrane, the 16,000 g supernatant was spun for 90 min at 200,000 g, and its pellet was resuspended in the hypotonic buffer and stored in liquid nitrogen.
To isolate plasma membranes, the 16,000 g pellet of homogenized cells was resuspended in medium 1 and centrifuged for 10 min at 1,000 g. The subsequent pellet was discarded and the supernatant was centrifuged at 17,000 g for 20 min. The pellet was resuspended in 2 ml of medium 1 and layered on a 15-ml of medium (medium 11 For a prolonged incubation with furosemide, an adipose tissue culture method was used. Under sterile conditions isolated fat pads were gently rinsed, cut in small pieces, and placed in 100 X 20-mm tissue culture dishes (-3 g/dish) containing Parker's medium 199 following the method of Maloff and Lockwood (18) . When used enough furosemide to give a final concentration of 0.1 mM was added to the incubation medium. The dishes were then incubated at 370C for 48 h under an atmosphere of 95% 02/5% CO2 with the media changed after 24 h.
Measurement of 3-OMG flux. Glucose transport was assessed by measuring equilibrium exchange rates of 3-OMG using tritium-labeled 3-OMG as a tracer and a modification of the oil flotation method of Whitesell and Glieman (19) . Isolated cells were incubated with a given concentration of 3-OMG in a Krebs-Ringer buffer (-10% cytocrit) for 30 min at room temperature. The cell suspension was then briefly centrifuged (30 s at 500 g) to reduce its volume to a 40-50% cytocrit. Insulin or furosemide when used, and 3-OMG solution (for controls) were added this stage to given final concentrations and hematocrits of 22-27% (see above). 200-Ml aliquots of this cell suspension were transferred into centrifuge tubes (12 X 75-mm polypropyline), and then, incubated without shaking for 45 min at 37°C. The flux measurements were initiated by injecting 10 Ml of 0.9 MCi of labeled 3-OMG directly into the cell suspension with an automatic pipette and vortexed gently for 3 s. The flux was terminated by the addition of 3.5 ml of ice cold Krebs-Ringer bicarbonate buffer containing 0.3 mM of phloretin and 0.15% vol/vol of ethanol. I ml of ice-cold silicone oil (relative density, 0.99; viscosity, 100 centistokes) was layered on top of the mixture and the tubes were centrifuged immediately for 1 min at 2,500 g. The packed cells on top were then removed with a pipe cleaner and placed in counting vials with 10 ml of scintillation fluid (Hydrofluor, National Diagnostics, Somerville, NJ) vortexed vigorously and their radioactivities were counted. Extracellular trapped radioactivity was measured by adding phloretin solution to cells before injection of isotopic 3-OMG.
Cytochalasin B binding assays. Cytochalasin B binding assay was carried out by a centrifugation method that was described from our laboratory (20) (Fig. 2) . Furosemide treatments also reduced the 3-OMG space of adipocytes significantly and this effect is apparently dosedependent (Fig. 2) . This is most likely due to cell shrinkage (23) or cell lysis. Nevertheless, analyses of the flux data using the sugar space observed (Sm:O) for each furosemide concentration shows that the inhibition increases in a simple, saturable manner as the concentration of furosemide in the incubation was increased (Fig. 3 A) . The furosemide concentration that reduced the flux rate by 50% (apparent inhibition constant, Kj) is -4-5 mM irrespective ofthe three 3-OMG concentrations used (Fig. 3 A) . When the same data were plotted as a function of 3-OMG for each furosemide concentration ( Fig. 1) , it is evident that the inhibition is due to a reduction in rmax without any significant change in the Km value, indicating a noncompetitive mode of inhibition. The 3-OMG fluxes of insulin-stimulated adipocytes were also inhibited by furosemide (Figs. 1 and 3 B) . The pattern of Piretanide and hydrochlorothiazide also inhibited 3-OMG equilibrium flux in a similar manner as furosemide, with a Ki value of -4 mM (data not shown). Bumetanide, however, did not show any significant inhibition at the concentrations up to 3 mM (solubility limit).
Cytochalasin B, a well-established specific inhibitor of glucose transport of adipocytes, binds to purified microsomal and plasma membranes of adipocytes (16, 17) . Scatchard analyses of these bindings indicated that there are at least two saturable binding components at the ligand concentration range of up to 10-5 M. The ligand binding to one of these components is displaced specifically by D-glucose, but not by L-glucose (16) . The difference in the ligand bindings observed between these two isomers are taken as the glucose-sensitive binding (16, 20) .
Effects of furosemide on this glucose-sensitive, cytochalasin B binding to microsomal and plasma membrane preparations were studied by assaying the ligand binding in the presence of 500 mM L-and D-glucose. In a series of experiments (pretreatment series), cells were first incubated with a given concentration of furosemide prior to their membrane subfractionation. In other experiments (posttreatment series), the membranes were prepared first, then incubated in the presence of furosemide and its effect on the ligand binding was assessed. Both of the furosemide treatments inhibited the cytochalasin B binding of both the microsomal and plasma membranes equally, regardless of whether in basal or in insulin-stimulated states. This is illustrated in Fig. 4 with microsomal membrane preparation of insulin-stimulated adipocytes.
The effects of furosemide on the glucose-sensitive cytochalasin B binding activities of these membrane preparations at both basal and insulin-stimulated states were further analyzed by Scatchard plot. In each case, when the incubation time with furosemide is fixed, BT (total binding capacity) of the glucose-sensitive binding was increasingly reduced as the furosemide concentration was raised in the incubation without affecting affinity (or KD) of the binding significantly. This is illustrated in Fig. 5 using plasma membranes prepared from basal state of adipocytes as an example, and the results with all preparations are summarized in Table I . Pretreatment appears slightly more effective than posttreatment throughout all preparations. This may be simply due to the additional exposure to the drug during membrane preparation involved in the pretreatment experiments. Data presented in Table I (16, 19) expressing bound in picomoles per assay tube on the x-axis. The assay mixture contained plasma membranes of protein concentrations 450, 360, and 260 Ag/ml for control, 1 the effect is saturable with a simple stoichiometry (Fig. 6) . For a 2-h posttreatment (30 min at room temperature followed by 90 min at 40C) the 50% inhibition occurred at the furosemide concentration of -3.5 mM. This apparent Ki value was not significantly different between microsomes and plasma membranes. For an 18-h posttreatment, the concentration that effects 50% inhibition was reduced to -0.9 mM for basal microsomes and 0.7 mM for insulin-stimulated microsomes. These findings indicate that the basal and insulin-stimulated states are equally sensitive to the inhibition. The time dependence of the furosemide effect was already evident in the observed reductions in the apparent Ki value between 2-h and 18-h incubations (Fig. 6) . Using a total particulate fraction of adipocytes (150,000 g fraction), the time course of the development of the inhibitory effect on the glucose-sensitive cytochalasin B binding was followed for 32 h (Fig. 7) . With the furosemide concentration of 1 mM, the inhibition developed as an exponential function of time with a first order rate constant of '-0.12/h at 4°C.
In an attempt to examine if the furosemide effect is reversible, a 150,000 g preparation preincubated with 6 mM furosemide for 3 h at 40C was, after separation by centrifugation, resuspended into a furosemide-free medium (a final furosemide concentration <0.06 mM) for 3 h at 40C. This procedure reduced the inactivation on the glucose-sensitive cytochalasin B binding activity from 71% down to 25%, indicating that the inactivation is only slowly reversible (data not illustrated).
The effects of longer term incubation with a lower concentration of furosemide on 3-OMG flux was also examined. Adipose pads were incubated for 48 h at 37°C with or without 
Discussion
We have shown in this study that furosemide inhibits the 3-OMG equilibrium exchange flux in isolated rat adipocytes. The inhibition is independent of insulin since flux in basal as well as insulin-stimulated adipocytes are affected equally. We have also shown that furosemide inhibits the glucose-sensitive cytochalasin B binding activities of both plasma membranes and microsomal membranes of adipocytes. There is ample evidence that glucose-sensitive cytochalasin B binding proteins are the glucose transport carrier molecules in adipocytes and other cells (16, 20, 25) . In adipocytes, these binding proteins exist in two pools, namely in plasma membranes and microsomal membranes, representing active and reserve pools of carrier, respectively (16, 17 (12, 26, 27) . Nevertheless, in view of the time-dependent, progressive, and poorly reversible nature of the observed effects, even these low blood levels could significantly inhibit glucose transport in peripheral tissues in vivo ifdrug therapy is continued for extended periods of time. In fact, our preliminary results show that after 48 h incubation at 370C furosemide at a concentration as low as 0.1 mM inhibits 50% of transport function. The comparison of effective in vivo vs. in vitro concentrations is complicated by possible enrichment of the drug at specific cellular sites and lack of detailed information on volume of distribution and systemic fate of diuretic agents. Evidence of progressive accumulation of furosemide in renal tissue has been observed (28, 29). The loop diuretic ethacrynic acid is also known to be accumulated by kidney slices to concentrations 10-fold higher than those in the incubation media (30) . In other in vitro systems the effective concentrations of furosemide are not markedly different from those causing effects reported in this paper. The concentration of furosemide in perfusion medium that inhibits sodium reabsorption maximally in isolated perfused renal tubule is 1 mM (31). The effective concentration for inhibition of sodium transport in the toad bladder is 0.8 mM (32) . Taken together, these considerations suggest that the drug-induced inhibition of glucose transport in peripheral tissues could contribute to the glucose intolerance observed in patients receiving diuretic therapy. Furthermore, our results demonstrate that hydrochlorothiazide and piretinide were as effective as furosemide, while bumetanide was significantly less potent. This is in accordance with reports that bumetanide in equivalent diuretic dosage may be less prone to cause glucose intolerance (33, 34) .
In conclusion, furosemide and other diuretics inactivate in vitro the glucose transport carrier of adipocyte independent of insulin. We propose that this may contribute to the glucose intolerance in patients receiving diuretic therapy.
